Teresa Knoop
PRESENTERS
Click on each link below for a printable file.
Suzanne Walker CRNP, MSN, AOCN, BC
Suzanne Walker is a nurse practitioner and coordinator for thoracic malignancies at Penn Presbyterian Medical Center in Philadelphia. In addition to her clinical role, Ms. Walker is also a member of the teaching faculty at the University of Pennsylvania School of Nursing in the Adult Oncology Minor/Post Master’s Certificate program. Ms. Walker has been involved in the Oncology
Nursing Society at both the local and national level, and she has lectured and written on numerous cancer related topics including lung cancer and novel cancer therapeutics. She is also finishing her PhD in nursing at the University of Arizona.
Amy Goodrich, NP
Frank dela Rama, RN, MS, AOCNS
Maura Abbott is an Assistant Professor of Nursing and Oncology Program Director Columbia University School of Nursing. She is also a Nurse Practitioner in the Columbia University Medical Center Department of Hematology/Oncology.
Brenda Nevidjon RN, MSN, FAAN
Brenda Marion Nevidjon is the Chief Executive Officer of the Oncology Nursing Society (ONS), a professional association of close to 40,000 members committed to promoting excellence in oncology nursing and quality cancer care. Her
career has included clinical, academic, and executive positions in oncology and general health care settings. After two decades in oncology clinical and administrative settings, she transitioned to health care executive practice, culminating with her being the first nurse and the first women to be chief operating officer of Duke University Hospital.
Immediately before joining ONS as chief executive Ms. Nevidjon was a professor of nursing at the Duke School of Nursing. Her bachelors’ degree is from Duke University, her master’s from the University of North Carolina, and she has taken doctoral studies at the Fielding Graduate Institute and Duke School of Nursing. Ms. Nevidjon also completed the Johnson & Johnson - Wharton Fellows Program in Management for Nurse Executives and was in the inaugural class of the Robert Wood Johnson Nurse Executive Program. Among her honors, she is a fellow in the American Academy of Nursing.
Dr. Sasine is the Director of the CAR T Cell Program in the Division of Hematology and Medical Oncology at the UCLA School of Medicine. He received a Bachelor of Science in Biology at the University of Northern Colorado and completed his medical degree at the University of Miami Miller School of Medicine in Miami, Florida. He then completed Internal Medicine Residency, Hematology/Oncology Fellowship, an Advanced Fellowship in Hematopoietic Cell Transplantation, and a PhD in cell and molecular biology at UCLA. Dr. Sasine established and continues to lead the Chimeric Antigen Receptor (CAR) T Cell Program at UCLA. He primarily treats patients in need of cellular therapies and leads several clinical trials. He spends more than half his time in a translational research lab, studying how cancer cells interact with their non-malignant neighboring cells.
Frank dela Rama is an Oncology/Genomics Clinical Nurse Specialist at Sutter Palo Alto Medical Foundation and a guest lecturer at the University of California San Francisco Graduate School of Nursing. Mr. delaRama has given numerous prostate cancer presentations at both local and national conferences. In addition, he serves on the advisory board for Oncology Nursing News and Conquer Magazine, as well as serving as the prostate cancer for the Academy of Oncology Nurse Navigators’ Journal of Oncology Navigation and Survivorship.
Teresa Knoop is an Assistant Director of the Clinical Trials Shared Resource at the Vanderbilt-Ingram Cancer Center in Nashville, TN. She graduated from Murray State University in Murray,KY with a BSN and earned her Master’s Degree in Nursing from the Vanderbilt University School of Nursing. Teresa is an Advanced Oncology Certified Nurse through the Oncology Nursing Society and is a Certified Clinical Research Professional through the Society of Clinical Research Associates. She has published articles in nursing journals and speaks frequently on the topics of molecularly targeted cancer therapies and cancer clinical trials.
AnnMarie Lee Walton, PhD, MPH, RN, OCN, CHES
Copyright 2019 GLAONS All rights reserved.
Maura Abbott
Dr. Joshua Sasine
Amy Goodrich, RN, MSN, CRNP, Research Associate, is a Nurse Practitioner in the
Hematologic Malignancies Program and Research Nursing Manager at The Johns
Hopkins Kimmel Cancer Center in Baltimore, Maryland. Ms. Goodrich manages patients with various types of hematologic malignancies, concentrating on the lymphomas. She also manages the Cancer Center’s research nurses and is extremely involved in researchoperations.
Ms. Goodrich earned her Master’s Degree in 2000 as an Acute Care Nurse Practitioner from the Johns Hopkins University and her undergraduate nursing degree from the University of Pittsburgh.
Dr. AnnMarie Walton is a tenure-track Assistant Professor at the Duke University School of Nursing where she conducts research to understand and minimize occupational exposure to known carcinogens. Dr. Walton completed a post-doctoral fellowship focused on interventions at the University of North Carolina at Chapel Hill School of Nursing, earned her PhD in nursing from the University of Utah, her master’s in public health and bachelor’s in nursing from the
University of North Carolina at Chapel Hill, and a bachelor’s degree in community health education from the University of Maryland. Her dissertation work was informed by the combination of her educational preparation and over ten years of clinical experience caring for patients with acute leukemia. Her dissertation examined the pesticide protective behaviors of Latino migrant and seasonal farmworkers and resulted in an educational toolkit developed with
farmworker health outreach workers. Her postdoctoral research focused on understanding the protective behaviors of Nursing Assistants handling antineoplastic drug contaminated excreta and was informed by her clinical practice, her advocacy experience and a bit of serendipity. Dr.Walton has an R21 proposal under review at NIOSH to look at the impact of USP &
requirements on minimizing surface contamination with antineoplastic drugs and to examine differences in surface contamination in oncology and non-oncology areas where those drugs are administered. Dr. Walton has been active in legislative efforts to mandate safer handling of hazardous drugs and recently lead the ONS/HOPA joint position statement on safe handling of
hazardous drugs. Today, Dr. Walton will talk about USP & requirements and share some recent results from her pilot study to examine surface contamination with antineoplastic drugs in inpatient oncology settings.